Progress in the treatment of invasive bladder cancer

Current Opinion in Urology

Volumn 6, Issue 5, 1996, Pages 280-285

  Javle, Milind ^a   Raghavan, Derek ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; GALLIUM NITRATE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; MITOMYCIN C; PACLITAXEL; VINBLASTINE; VINCA ALKALOID;

ADJUVANT CHEMOTHERAPY; BLADDER CANCER; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CYSTECTOMY; HUMAN; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0029841599     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-199609000-00011     Document Type: Short Survey

References (35)

1. Devesa SS, Blot WJ, Stone BJ, Miller BA, Tarone, RE, Fraumeni JF Jr: Recent cancer trends in the United States. J Natl Cancer Inst 1995, 87:175-182.
2. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 1996, 65:5-27.
3. Prout GR Jr, Griffin PP: Bladder cancer as a systemic disease. Cancer 1979, 3:2532-2539.
4. Raghavan D, Shipley W, Garnick M, Russell PJ, Richie JP: Biology and management of bladder cancer. N Engl J Med 1990, 322:1129-1138.
5. Richie JP: Surgery for invasive bladder cancer. Hematol Oncol Clin N Am 1992, 6:129-134.
6. Raghavan D, Huben R: The management of bladder cancer. Curr Probl Cancer 1995, 19:1-64. General review of biology and management of bladder cancer, including surgical approaches, prognostic markers, and new treatment approaches.
7. Puppo P, Perachino M, Ricciotti G, Bozzo W, Galluci M, Carmignani G: Laparoscopically assisted transvaginal radical cystectomy. Eur Urol 1995, 27:80-84. Report of laparoscopic transvaginal exenteration in five patients. The procedure had a high patient acceptability but was expensive. Urinary diversion procedures may be technically difficult with this approach. Although interesting, the procedure has not yet been compared with conventional radical cystectomy for patients with bladder carcinoma.
8. Schoenberg MP, Walsh PC, Breazeale DR, Marshall FF, Mostwin JL, Brendler CB: Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10 year follow up. J Urol 1996, 155:490-494. Review of surgical experience with nerve-sparing cystoprostatectomy, showing excellent local control rates; the actuarial 10-year survival figures are influenced by the fact that 52% of cases did not have invasive disease. Return of sexual potency was influenced by the age of the patients.
9. Pollack A, Zagars GK, Swanson DA: Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. Int J Radiat Oncol Biol Phys 1994, 30:267-277.
10. Zelefsky MJ, Leibel SA, Kutcher GJ, Kelson S, Ling CC, Fuks Z: The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma. Cancer J 1995, 1:142-150.
11. Cole DJ, Durrant KR, Roberts JT, Dawes PJ, Hopewell JW: A pilot study of accelerated fractionation in the radiotherapy of invasive cancer of the bladder. BR J Radiol 1992, 65:792-798.
12. Scher HI, Logothetis CJ: Chemotherapy of advanced bladder cancer. In Principles and Practice of Genitourinary Oncology. Edited by Raghavan D, Scher HI, Leibel S, Lange PH. Philadelphia: Lippincott Raven: 1996: In press.
13. Roth BJ, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, Hudes GR, Schultz SM, Loehrer PJ: Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994, 12:2264-2270.
14. Stadler W, Kuzel T, Raghavan D et al: A phase II study of gemcitabine in the treatment of patients with advanced transitional cell carcinoma [Abstract]. Proc Am Soc Clin Oncol 1995, 14:241.
15. Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA: A randomized comparison of cisplatin alone or in combination with methotrexate vinblasgtine and doxorubicin in patients with metastatic urothelial carcinoma [Abstract]. J Clin Oncol 1992, 10:1066.
16. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, Kilboum RG: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial carcinoma. J Clin Oncol 1990, 8:1050-1055.
17. Saxman SB, Loehrer PJ, Propert K, Kuebler JP, Crawford ED, Tannock I, Raghavan D, Stuart-Harris, R, Trump D, Einhorn LH: Long term follow up of phase III Intergroup study of MVAC vs. cisplatin in metastatic urothelial carcinoma [Abstract]. Proc Am Soc Clin Oncol 1996, 15:248.
18. Schultz PK, Herr HW, Zhang ZF, Bajorin DF, Seidman A, Sarkis A, Fair WR, Scherr D, Bosl GJ, Scher HI: Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol 1994, 12:1394-1401.
19. Malstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E and the Nordic Cooperative Bladder Cancer Study Group: Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. J Urol 1996, 155:1903-1906. Late follow-up of one of the very few randomized trials to show a survival benefit from neoadjuvant chemotherapy in invasive (t1, grade 3 and T2-T4) bladder cancer. In this study 325 patients underwent cystectomy alone or cystectomy preceded by two cycles of cisplatin and doxorubicin. After 5 years, the overall survival rate for the chemotherapy group was 59% versus 51% for the surgery only group (P=0.1); the cancer-specific survival rates were 64 and 54%, respectively. The difference in overall survival for patients with T3 and T4 disease was statistically significant.
20. Scattoni V, Da Pozzo L, Nava L, Broglia L, Galli L, Torelli T, Camp B, Maffezzini M, Rigatti P: Five-year results of neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy plus raidcal cystectomy in locally advanced bladder cancer. Eur Urol 1995, 28:102-107. Italian study of neoadjuvant CMV chemotherapy in which 69 patients were treated for invasive bladder cancer, with 60% disease-free survival at median follow-up of 4 years; inappropriate patient exclusions altered the statistics, which should be reviewed carefully by the reader.
21. Ghersi D, Stewart L, Parmar M, Coppin C, Raghavan D, Martinez-Pineiro J, Wallace MA: Does neoadjuvant cisplatin based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Br J Urol 1995, 75:205-213. A meta-analysis of all randomized trials testing efficacy of neoadjuvant chemotherapy for invasive, clinically nonmetastatic bladder cancer, did not reveal a survival advantage with neoadjuvant chemotherapy.
22. Hall RR for MRC Advanced Bladder Cancer Working Party, EORTC GU Group, NCI Canada, Norwegian Bladder Cancer Group, Australian Bladder Cancer Study Group, Club Urologica Espanol de Tratamiento and FinBladder: Neo-adjuvant CMV chemotherapy and cystectomy or radiotherapy in muscle invasive bladder cancer. First analysis of MRC/EORTC Intercontinental Trial [Abstract]. Proc Am Soc Clin Oncol 1996, 15:244.
23. Logothetis CJ, Swanson D, Amato R, Banks M, Finn L, Ayala A, Ro J, Babaian R, Dinney C, Ellerhorst HJ, et al:. Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. J Urol 1996, 155:1241-1245. Randomized comparison of cystectomy followed by five cycles of adjuvant MVAC versus two cycles of MVAC, followed by cystectomy and then three cycles of MVAC; trial revealed no survival benefit.
24. Raghavan D: Editorial: Perioperative chemotherapy for invasive bladder cancer - what should we tell our patients? J Urol 1996, 155:1246-1247.
25. Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, Kern W, Sakamoto J, Krailo M, Goshen S: The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a propsective comparative trial. J Urol 1991, 145:459-463.
26. Raghavan D: Editorial comment: Adjuvant chemotherapy following cystectomy for invasive bladder cancer. J Urol 1991, 145:465-466.
27. Stockle M, Meyehburg W, Wellek S, Voges G, Gertenbach U, Thuroff JW, Huber C, Hohenfellner R: Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992, 148:302-307.
28. Freiha F, Reese J, Torti FM: A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996, 155:495-500. Randomized trial that revealed a disease-free survival advantage, but only a statistical trend towards overall survival benefit, among patients with invasive bladder cancer undergoing cystectomy plus adjuvant chemotherapy (cisplatin, methotrexate, vinblastine) compared with those undergoing cystectomy alone. Only 55 patients were randomized, and thus the power of the trial is small.
29. Wei C-H, Hsieh R-K, Chiou T-J, Chen K-K, CHang LS, Chen P-M: Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience. J Urol 1996, 155:118-121. Small series of patients with invasive, high-risk transitional cell carcinoma of bladder or upper tracts, treated with modified CMV, but with relatively short follow-up; survival data appear somewhat inconsistent and should be studied closely.
30. Coppin C, Gospodarowicz M, Dixon P: Improved local control of invasive bladder cancer by concurrent cisplatin and pro-operative or radical radiation [Abstract]. Proc Am Soc Clin Oncol 1992, 11:198.
31. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efird JT: Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 1993, 329:1377-1382.
32. Housset M, Maulard C, Chretien Y, Dufour B, Delanian S, Huart J, Colardelle F, Brunel P, Baillet F: Combined radiation and chemotherapy for invasive transitional cell carcinoma of the bladder: a prospective sutdy. J Clin Oncol 1993, 11:2150-2157.
33. Tester W, Porter A, Asbell S, Coughlin C, Heaney J, Krall J, Martz K, Venner P, Hammond D: Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Rad Oncol Biol Phys 1993, 25:783-790.
34. Given RW, Parsons JT, McCarley D, Wajsman Z: Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a five-year follow-up. Urology 1995, 46:499-505. Ninety-four patients with invasive bladder carcinoma were treated with transurethral resection followed by two or three cycles of CMV or MVAC and then radiotherapy for selected cases. After a median follow-up of 5 years relapse-free survival was 49%. However, this study included patients who were poor surgical risks and patients with advanced T4 tumors. Radiotherapy was offered only to 49 out of 90 patients, and questions regarding trial design and the relevance of the results have been raised.
35. Angulo JC, Sanchez-Chapado M, Lopez JI, Flores N: Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors. J Urol 1996, 155:1897-1902.